Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL19260764

COc1cc2c(NC(C)C)c3ccccc3nc2cc1OCCCN1CCOCC1.O=C(O)C(F)(F)F

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 7/20 0.51
AURKA O14965 6/20 0.51
MAP2K1 Q02750 5/20 0.51
AURKB Q96GD4 5/20 0.51
SRC P12931 3/20 0.51
KDR P35968 3/20 0.51
MET P08581 3/20 0.51
RET P07949 2/20 0.51
ROCK2 O75116 1/20 0.51
ALDH1A1 P00352 1/20 0.51
LCK P06239 1/20 0.51
FYN P06241 1/20 0.51
MAPT P10636 1/20 0.51
PDGFRA P16234 1/20 0.51
LTK P29376 1/20 0.51
TTK P33981 1/20 0.51
MAP2K2 P36507 1/20 0.51
BTK Q06187 1/20 0.51
TYRO3 Q06418 1/20 0.51
TNK2 Q07912 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19260556 0.93 SRC (0.56) EGFRAURKAMAP2K1AURKBSRC
Trifluoroacetic Acid SCHEMBL20720721 0.88 CACNA2D1 (0.52) KDRMETFLT1
Trifluoroacetic Acid SCHEMBL19260683 0.88 CACNA2D1 (0.52) KDRMETFLT1
Trifluoroacetic Acid SCHEMBL19260639 0.88 CACNA2D1 (0.52) KDRMETFLT1
SCHEMBL19260641 0.86 CACNA2D1 (0.58)
Trifluoroacetic Acid SCHEMBL20720681 0.85 EHMT2 (0.55)
SCHEMBL19260538 0.85 MAP2K1 (0.61) EGFRMAP2K1SRCKDRRAF1
Trifluoroacetic Acid SCHEMBL20720656 0.84 CACNA2D1 (0.50) KDRMETALDH1A1FLT1
Trifluoroacetic Acid SCHEMBL19260564 0.84 EHMT2 (0.50)
Trifluoroacetic Acid SCHEMBL20336968 0.83 AURKA (0.47) EGFRAURKAMAP2K1AURKBSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11254651-B2 Histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2022-02-22 US disclosed
EP-3416963-B1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2021-07-28 EP disclosed
US-20190047981-A1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2019-02-14 US disclosed
EP-3416963-A1 HISTONE METHYLTRANSFERASE INHIBITORS Global Blood Therapeutics, Inc. (US) 2018-12-26 EP disclosed
WO-2017142947-A1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2017-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190047981-A1 HISTONE METHYLTRANSFERASE INHIBITORS EHMT1, EHMT2, BMI1 EGFR 4848/4885AURKA 3424/4885MAP2K1 4257/4885
US-11254651-B2 Histone methyltransferase inhibitors EHMT1, EHMT2, BMI1 EGFR 4848/4885AURKA 3424/4885MAP2K1 4257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.